Overly Restrictive Clinical Trial Exclusion Criteria May Block Patients ...
Clinical trials often exclude patients with comorbidities, limiting access to investigational therapies. A study led by Dr. Montalban Bravo explored treating 'unfit' AML and MDS patients with azacitidine and vorinostat, showing feasibility and clinical benefit. Results suggest relaxing exclusion criteria could expand trial access and benefit patients with poor prognoses.
Reference News
Overly Restrictive Clinical Trial Exclusion Criteria May Block Patients ...
Clinical trials often exclude patients with comorbidities, limiting access to investigational therapies. A study led by Dr. Montalban Bravo explored treating 'unfit' AML and MDS patients with azacitidine and vorinostat, showing feasibility and clinical benefit. Results suggest relaxing exclusion criteria could expand trial access and benefit patients with poor prognoses.